Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEMOMYOCT Misoprostol Trial
2024-513617-13-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Fibromyoma (LM) comparing Misoprostol (MisoOne) with Placebo (2 arms). Planned start Dec 2024; status: authorised.
02
Drugs
misoprostol
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on 2024-513617-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513617-13-00.